Enanta Pharmaceuticals, Inc. (ENTA)

Market Cap	192.39M
Revenue (ttm)	71.96M
Net Income (ttm)	-115.33M
Shares Out	21.19M
EPS (ttm)	-5.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,278
Open	9.34
Previous Close	9.42
Day's Range	8.98 - 9.39
52-Week Range	8.51 - 17.80
Beta	0.57
Analysts	Buy
Price Target	20.00 (+120.26%)
Earnings Date	Nov 25, 2024

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the ma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 21, 2013
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: ENTA
• Website: https://www.enanta.com

Financial Performance

In 2023, Enanta Pharmaceuticals's revenue was $79.20 million, a decrease of -8.07% compared to the previous year's $86.16 million. Losses were -$133.82 million, 9.91% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for ENTA stock is "Buy." The 12-month stock price forecast is $20.0, which is an increase of 120.26% from the latest price.

Price Target

$20.0

(120.26% upside)

Analyst Consensus: Buy